Literature DB >> 4014943

Vocal function following carbon dioxide laser surgery for glottic carcinoma.

M Hirano, Y Hirade, H Kawasaki.   

Abstract

Vocal function following laser surgery for glottic T1a carcinoma was evaluated in 17 patients and compared to vocal function following radiotherapy in 14 patients. The results are summarized as follows. 1) A slight degree of hoarseness was found more frequently following laser surgery than following radiotherapy. The quality of hoarseness was rough and breathy in most cases. 2) In stroboscopic examination, incomplete glottal closure and diminution or lack of vibration of the operated vocal fold were frequently observed following laser surgery. 3) There was no marked difference in maximum phonation time, mean airflow rate, fundamental frequency range of phonation, intensity range of phonation, and intensity-flow ratio between the laser and the radiotherapy groups. On the basis of these results, we conclude that there is little difference in vocal function between postlaser and postradiotherapy patients as far as conversational voice is concerned.

Entities:  

Mesh:

Year:  1985        PMID: 4014943

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  12 in total

Review 1.  Management of laryngeal dysplasia: a review.

Authors:  Maziar Sadri; Jeremy McMahon; Andrew Parker
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-07-06       Impact factor: 2.503

2.  Quantitative analysis of voice quality in early glottic laryngeal carcinomas treated with radiotherapy.

Authors:  A S Dagli; H F Mahieu; J M Festen
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

3.  CO2 laser in the diagnosis and treatment of early cancer of the vocal fold.

Authors:  M Remacle; G Lawson; J Jamart; M Minet; J B Watelet; M Delos
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 4.  Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer.

Authors:  Laura Warner; Jessal Chudasama; Charles G Kelly; Sean Loughran; Kenneth McKenzie; Richard Wight; Paola Dey
Journal:  Cochrane Database Syst Rev       Date:  2014-12-12

5.  The recruitment of patients to trials in head and neck cancer: a qualitative study of the EaStER trial of treatments for early laryngeal cancer.

Authors:  D W Hamilton; I de Salis; J L Donovan; M Birchall
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-20       Impact factor: 2.503

Review 6.  Health status and voice outcome after treatment for T1a glottic carcinoma.

Authors:  A Jeanne G E Peeters; Christine D L van Gogh; Kim M Goor; Irma M Verdonck-de Leeuw; Johannes A Langendijk; Hans F Mahieu
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-09       Impact factor: 2.503

7.  Videolaryngoscopic and videostroboscopic evaluation following laser CO(2) and conventional cordectomy of T(is) and T(1) glottic carcinoma.

Authors:  Magdalena Lachowska; Ewa Osuch-Wójcikiewicz; Antoni Bruzgielewicz
Journal:  Arch Med Sci       Date:  2010-09-07       Impact factor: 3.318

8.  Voice quality after endoscopic laser surgery and radiotherapy for early glottic cancer: objective measurements emphasizing the Voice Handicap Index.

Authors:  Faustino Núñez Batalla; Maria Jesús Caminero Cueva; Blanca Señaris González; José Luis Llorente Pendás; Carmen Gorriz Gil; Aurora López Llames; Ramón Alonso Pantiga; Carlos Suárez Nieto
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-11-13       Impact factor: 2.503

9.  A modified false vocal fold flap for functional reconstruction after frontolateral partial laryngectomy: a comparison with conventional open resection and laser cordectomy.

Authors:  Kai J Lorenz; Roland Kohnle; Heinz Maier
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2013-10-23

10.  Transoral laser surgery for laryngeal cancer.

Authors:  Vlad C Sandulache; Michael E Kupferman
Journal:  Rambam Maimonides Med J       Date:  2014-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.